Orthopedics Medical News about lasofoxifene; osteoporosis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Lasofoxifene: Evidence of its therapeutic value in osteoporosis
Core Evidence, 07/31/09

Gennari L et al. – There are three (phase II or phase III) clinical trials that clearly demonstrate efficacy and safety of this new SERM in the suppression of bone loss and the prevention of vertebral and nonvertebral fractures. Moreover, lasofoxifene treatment also reduced breast cancer risk and the occurrence of vaginal atrophy. With its increased potency and efficacy on the prevention of nonvertebral fractures lasofoxifene may be an alternative and cost–effective therapy for osteoporosis in postmenopausal women.

<< Previous
Osteoarthritis and Glucosamine

Next >>
Optimising use of the mini C-arm in foot and ankle surgery